-+ 0.00%
-+ 0.00%
-+ 0.00%

GENFIT Highlights Long-Term Commercial Opportunity for its MASH Diagnostics Technology

Barchart·09/09/2026 00:30:00
Listen to the news

Lille (France), Cambridge (Massachusetts, United States), September 9, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today highlights the long-term commercial opportunity associated with NIS4® and next-generation NIS2+®, its proprietary non-invasive NISTM diagnostic technologies aimed to identify patients with “at-risk MASH”.

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.